Schlosser Mario 4

What Happened

• Mario Schlosser, a director of Oscar Health (OSCR), converted derivative securities and exercised stock options on June 23, 2026, then sold shares that same day. He sold a total of 1,027,500 shares in multiple open-market transactions for aggregate proceeds of approximately $30.18 million. Separately, he exercised 660,000 options at $9.75 per share, paying about $6.435 million to acquire those shares.
• The sold shares came from conversions of derivative securities (1,027,500 shares converted) and open-market sales executed at weighted-average prices in the high-$20s to low-$30s. The filing shows the sales were effected under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: June 23, 2026 (Form 4 filed June 25, 2026).
• Sales: 1,027,500 shares sold for total proceeds ≈ $30,183,414 (multiple lots; weighted-average prices reported; price ranges per filing: about $28.08–$30.04).
• Option exercise: 660,000 shares acquired at $9.75 each for $6,435,000 (option fully vested and exercisable; expires Dec 16, 2029).
• Conversions: 1,027,500 shares resulted from conversion of derivative securities (Class B→Class A mechanics noted in filing).
• Plan/notes: Sales effected pursuant to a Rule 10b5-1 plan adopted March 24, 2026 (footnote). Weighted-average price disclosures cover multiple trade prices; full per-price breakdown is available on request per the filing.
• Beneficial ownership: filing disclaims ownership of shares held of record by a trust except to the extent of pecuniary interest (filing footnote).
• Timeliness: Form 4 was filed two days after the transactions (filed 6/25 for transactions on 6/23).

Context

• This was primarily a sale/monetization event (insider sold shares after converting/exercising derivatives). Schlosser paid cash to exercise options (not a cashless exercise). The trades were executed under a pre-established 10b5-1 plan, which is commonly used to schedule sales and reduces questions about opportunistic timing. As always, insider selling is routine and not, by itself, a reliable signal of company prospects.